ABSTRACT
Purpose: Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has been utilized to identify distinct molecular subtypes, but there have been no reports investigating whether or not molecular subtyping is predictive of response to bevacizumab in ovarian cancer.
Experimental Design: DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes.
Associations between molecular subtype and the efficacy of randomly assigned therapy with bevacizumab were assessed. Conclusions: Molecular subtypes with the poorest survival (proliferative and mesenchymal) derive a comparably greater benefit from treatment that includes bevacizumab. Validation of our findings in an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, thereby reducing side effects and healthcare cost.
INTRODUCTION
Ovarian cancer has the highest mortality rate of all gynecologic malignancies 1 . Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Most patients initially respond to platinum-based chemotherapy but the majority relapse and die from drugresistant disease 2 .This underscores the significant clinical need for more effective and refined treatment strategies. Despite classifying epithelial ovarian cancer into high grade serous, endometrioid, clear cell and mucinous histologies, the disease continues to be treated with a "one size fits all" approach. Gene expression analysis of fresh frozen ovarian cancers performed in the Australian Ovarian Cancer Study and The Cancer Genome Atlas (TCGA) has led to a molecular classification of four subtypes of high-grade serous (HGS) ovarian cancer: proliferative, mesenchymal, immunoreactive and differentiated 3, 4 . In contrast to the original TCGA report, we recently demonstrated that these four subgroups have prognostic significance when well-annotated with complete clinical follow-up 5, 6 . Furthermore, we demonstrated that these molecular subtypes could also be used to classify high grade, advanced stage endometrioid and clear cell ovarian cancers 6 . However, the clinical practice of stratifying ovarian cancer patients into different targeted treatment subgroups based on their molecular classification has not yet been adopted.
In ongoing efforts to refine treatment approaches to ovarian cancer while acknowledging the unique biological differences between these four molecular subtypes of the disease, novel targeted agents are being developed and investigated. Of particular interest is, bevacizumab, an anti-angiogenic monoclonal antibody that binds to all isoforms of the vascular endothelial growth factor (VEGF)-receptor ligand VEGF-A. The Gynecologic Cancer Inter Group (GCIG) International Collaboration on Ovarian Neoplasms (ICON7) trial and the Gynecologic Oncology Group study 218 (GOG-218)
were two phase III trials in ovarian cancer which showed statistically significant improvements in median progression free survival (PFS) of 2.3 and 3.8 months, respectively, when bevacizumab was added to standard first-line chemotherapy 7, 8 . However, neither trial showed a statistically significant improvement in overall survival (OS) in unselected patients. This modest clinical improvement has led to limited use of bevacizumab in the frontline treatment of ovarian cancer. Unfortunately, there are currently no predictive biomarkers that can help to identify patients who would derive a larger clinical benefit from frontline treatment with bevacizumab. We now have information, based on gene expression data, that the mesenchymal and proliferative ovarian cancer molecular subtypes are both defined by overexpression of genes that are relevant to angiogenesis and VEGF-A, the target of bevacizumab [3] [4] [5] . Thus, an improved response to bevacizumab in ovarian cancer may be expected if it is used as a targeted therapeutic for patients within the angiogenic driven mesenchymal and proliferative subgroups. In this current study, we hypothesize that these gene expression-derived molecular subtypes can serve as biomarkers to identify patients with differential sensitivity to bevacizumab in ovarian cancer. In order to identify TCGA molecular subtypes, whole genome gene expression analysis was performed using stored formalin-fixed paraffin-embedded (FFPE) tumors from ICON7 trial participants who were treated with and without bevacuzimab 4, 7 . Clinical data for these patients was subsequently analyzed for potential sub-type specific differences in outcome when treated with and without bevacizumab. The primary objective of this study was to evaluate the therapeutic treatment impact of bevacizumab on PFS based on molecular subtyping. The secondary objective of this study was to assess the impact of treatment with bevacizumab on OS based on molecular subtyping,
MATERIAL AND METHODS

Study Subjects
Patients were derived from the AGO-OVAR11 trial, the German contribution to the ICON7 multicenter phase III trial in which patients with peritoneal, tubal or ovarian carcinoma were randomized to carboplatin and paclitaxel with or without bevacizumab 7 . Of 533 patients enrolled in the AGO-OVAR11 trial, paraffin-embedded tissue was available for a total of 423 patients with primary ovarian, fallopian tube or primary peritoneal cancer confirmed by expert gynecopathologic review 9, 10 . Adequate RNA (described below) was available from 391 patients, and expression array data for 359 patients passed quality control steps (described below). This resulted in a total of 359 patients for further analysis.
RNA Isolation
Using FFPE tumor, three 1mm cores were obtained from areas containing >70% tumor nuclei. Total RNA was isolated from these cores using a Qiagen AllPrep DNA/RNA FFPE kit according to the manufacturer's protocol using a Qiacube robot. RNA concentration was measured with a ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). Real time RT-PCR was performed to amplify small regions of two abundant mRNAs: the 18S rRNA and gACTB to assess RNA quality.
Whole Genome DASL Microarray Analysis
Specimens were randomly allocated to RNA extraction and assay run order. 
Gene Expression Quality Control
Gene expression data quality was assessed via residual minus versus average plots, box plots, and jitter plots to view experimental artifacts such as batch effects 10 . In addition, numerical measures such as stress and dfbeta, measures of the magnitude of change due to normalization, were utilized 11 .
Criteria for exclusion were median stress >1 (0 samples were excluded) and median dfbeta >1 (35 samples were excluded). Data were normalized on the log 2 scale via quantile normalization. Perprobe batch effects remaining after normalization were removed by calculating residuals from perprobe linear models 12 .
Molecular Subtype Assignment
Molecular classification was determined blinded to demographic and clinical information. Briefly, each given sample was assigned to a subtype according to similarity between observed expression and per-subtype expression centroids learned from TCGA. De novo clustering was also performed, confirming the existence of four subtypes (Appendix 1). In both TCGA and our own de novo clustering studies, consensus clustering approach was used to ensure that only stable clustering solutions were kept after multiple re-runs.
Statistical Analysis
As defined in the original ICON7 report 7 , primary endpoints were PFS and OS. Kaplan Meier curves and log rank tests were used to visualize unadjusted results. As observed previously 7 , nonproportional hazards were evident for PFS (p<0.0001). Thus, restricted means hypothesis tests were conducted for PFS over the duration of bevacizumab treatment (18 months) and at 36 and 42 months for unadjusted models. Restricted means measure the area under the survival curve, and so more accurately measure differences in outcome in the presence of non-proportional hazards.
Covariate-adjusted testing was conducted in a two-step manner. First, similar to a propensity score 13, 14 , a clinical risk score was calculated by fitting a Cox regression model to all patients based on high risk of progression (ICON 7 high risk group: suboptimally cytoreduced Stage III with >1.0 cm residual disease at the end of surgery, inoperable Stage III, all Stage IV ) 7 , age (continuous), histology (serous; other), and grade (1, 2 or 3). Second, the predicted value, the , was used as an offset in Cox models. Given the sample size, we focused on effect size and report actual p-values, using 0.05 as an indicator of statistical significance, and utilized Bonferroni multiple testing criteria for subgroup comparisons.
RESULTS
Patient Cohort
The baseline characteristics of the 359 patients included in the analysis were well balanced between treatment groups (Table 1) . 77.2% of tumors were of serous histology and one third of patients were at high risk of progression. An optimal cytoreduction (to residual disease of < 1 cm) was performed in 76.3% of patients. At a median follow-up of 26.9 months (range 0 -43.6), 226 patients (63%) had a PFS event and 91 patients (25%) had died.
TCGA-defined Molecular Subtype Determination
Molecular subtype assignment was as follows: 73 differentiated (20%), 122 immunoreactive (34%), 68 mesenchymal (19%), and 96 proliferative (27%). These frequencies are comparable to those found in prior studies 4 . When we applied unsupervised non-negative matrix factorization (NMF)
clustering with k=4 groups, the average cophenetic coefficient was 0.993, indicating high reproducibility of this classification (Chi square test P<0.001) ( Figure S1 , 2). Baseline characteristics within molecular subgroups are shown in Table 2 . Among mesenchymal and proliferative subgroups, 43% and 42% patients, respectively, met the criteria of the ICON7 high risk group, compared to 25% and 26% in the differentiated and immunoreactive subgroups, respectively 4 . Consistent with prior reports, patients with mesenchymal and proliferative tumors also had inferior PFS compared to the differentiated and immunoreactive subgroups (Figure 1 ) 5, 6 .
Bevacizumab Effects on PFS by Molecular Subtype
Univariate analysis was performed for PFS between treatment arms stratified by molecular subtypes Figure 1D , Table 3 ). Changes in PFS for the mesenchymal, immunoreactive, and differentiated groups remained non-significant in multivariate analysis (Table 3) .
Bevacizumab Effects on OS by Molecular Subtype
The overall survival data was not mature at the time of analysis, but preliminary analysis was performed using OS between treatment arms in molecular subtypes in a univariate analysis by Figure 2D , Table 3 ).
Changes in OS for the mesenchymal, immunoreactive, and differentiated groups remained nonsignificant in multivariate analysis (Table 3) .
Restricted Means Analysis for PFS by Molecular Subtype
As reported in the primary results for the clinical trial, there was a significant violation of the assumption of proportional hazards. Thus, we also assessed the effect of bevacizumab on PFS using a restricted means approach, as performed in the parent trial. During the first 18 months of therapy, which corresponds to the treatment duration of bevacizumab, the strongest bevacizumab treatment effect was observed in the proliferative group (p=0.0004) followed by the mesenchymal subgroup (p=0.0121); this treatment effect persisted within the proliferative subgroup only, as seen at 36 months (p=0.010) and 42 months (p=0.011) respectively (Table S1 ). Table 3) .
Bevacizumab Treatment Effects on PFS and OS
CONCLUSION
The precise role of anti-angiogenic therapy of ovarian cancer continues to evolve. While both GOG 218 and ICON7 showed improvement in progression free survival with the addition of bevacizumab to standard platinum based chemotherapy in the treatment of ovarian cancer, predicting which patients will derive the greatest benefit from this anti-angiogenic therapy has remained challenging. Through work performed by the Australian Ovarian Cancer Study, the TCGA and our own group, gene expression analysis has identified four distinct molecular subtypes of high grade serous ovarian cancer with prognostic significance. Of these four types, the mesenchymal and proliferative subtype share an angiogenic gene expression signature and may respond to antiangiogenic therapy.
Therefore, through this work, we investigated whether molecular subtyping by gene expression analysis could identify ovarian cancer patients who would preferentially benefit, in terms of PFS and OS, from the addition of bevacizumab to standard initial systemic therapy. Usingtranscriptional profiling on 129 ovarian cancers, an "angiogenesis signature" was described and validated in ten gene expression datasets and associated with improved OS 16 , but an unknown number of patients were treated with bevacizumab. For the current study, we hypothesized that bevacizumab may be more effective in those subtypes (the mesenchymal and proliferative) with upregulation of proangiogenic genes and/or upregulation of stromal components that may secrete proangiogenic factors. For example, overexpression of SOX11, a defining alteration in the proliferative subtype, is associated with increased microvessel density 17 . Mesenchymal tumors are characterized by HOX upregulation, an important promoter of capillary morphogenesis and angiogenesis through VEGF 18, 19 . Interestingly, the mesenchymal subtype of glioblastoma, a tumor which can also be divided into four unique molecular subtypes based on gene expression profling 20 , has the worst overall prognosis but appears to have an improved response to bevacuzimab 21 and is currently the subject of ongoing clinical investigation [http://clinicaltrials.gov/show/NCT01392209].
In addition, a recent study from Sandmann et al. used a NanoString based gene expression molecular classifier to stratify patients treated in the phase III frontline glioblastoma AVAglio trial into established molecular subtypes. All patients in this study who were treated with bevacizumab had an improvement of PFS but without an OS benefit. However, when stratified by molecular subtype, the proneural group showed a significant improvement in PFS and OS with the addition of bevacuzimab 22 . As in our current study, the work by Sandmann et al. demonstrated the feasibility of clinical application of gene expression based classifiers to select patients benefiting most from antiangiogenic treatment 22 . Additional studies in breast cancer and lymphoma have implemented clinically reliable and reproducible subtyping assays in other cancers 23,24 . Our study sought to establish the validity of stratifying ovarian cancer patients into molecular subtypes based on gene expression data to predict response to bevacizumab. Our results are strengthened by the use of samples from a large, randomized controlled clinical trial comparing the addition of bevacizumab to standard treatment versus standard treatment alone, with high quality robust clinical follow-up. Importantly, we were able to demonstrate the ability to obtain high quality gene expression data from FFPE tissues in 85% of cases. The Australian Ovarian Cancer Study
Group has recently evaluated the feasibility of using FFPE tissue in comparison to fresh frozen tissue from the same tumor and were able to correctly classify 80% of the FFPE samples 25 . In addition, they compared 1) PCR-based assays (low density arrays and Fluidigm), 2) the fluorescent oligonucleotide array NanoString and 3) a targeted RNA sequencing assay (Illumina). The NanoString assay emerged as the best clinically applicable platform and can be used in individual patients for molecular subtype assignment 25, 26 . The utility of molecular subtype assignment using the NanoString platform is currently being validated in 3000 retrospective ovarian cancer samples, by the Ovarian Tumor Tissue Analysis (OTTA) consortium. The use of FFPE has important clinical practicality in contrast to the TCGA's use of fresh frozen material which is less readily available and inconvenient to transport. Finally, an additional strength of our data lies in the fact that rather than creating another de novo molecular classification, we used the four gene signatures previously described by the Australian Ovarian Cancer Study 3 and validated by TCGA 4 . In contrast to the original TCGA report, we recently demonstrated that these four subgroups have prognostic significance when well-annotated with complete clinical follow-up 5, 6 . The proliferative and mesenchymal signatures had shorter survival when compared to the immunoreactive group (adjusted OR 1.52, 1.84, respectively). It is encouraging that bevacizumab appears to confer the greatest benefit for the two molecular subgroups (proliferative and mesenchymal) with the worst prognosis.
Interestingly, these two subtypes also showed the greatest benefit over the duration of bevacizumab therapy, which rapidly diminished following cessation of treatment. This suggests merit in investigating prolongation of bevacizumab therapy in patients with proliferative or mesenchymal tumors.
In this current work, we analyzed only a subset of the entire population of women treated on ICON7 but could be further strengthened by analysis of a replication cohort which was not available.
One limitation of our study was that it was limited to the German AGO samples. The number of missing data, due to missing available FFPE tissue, limited tumor tissue or purity, could skewthe remaining data to larger tumors that had inherently more available FFPE tissue. Different institutional protocols in preparation of the FFPE tumor tissue used in this study could also have had influence on the RNA quality and subsequent successful DASL array data in this study. However the samples were obtained from 98 different participating study sites in Germany, reducing the risk of site specific sample preparation. Importantly, our set mirrors the stages and histologies of all women enrolled, and like the parent trial 7 , a statistically significant improvement in PFS, but not OS, was subgroup. Similarly, this study was not powered to show statistically significant differences in PFS improvement between molecular subgroups. We nevertheless consider differences in the magnitude of PFS improvement within each subtype to be clinically relevant.
In order to move towards clinical application of gene expression based subtyping in ovarian cancer, our findings need to be validated retrospectively in a validation cohort. Despite significant differences between the ICON7 and the GOG218 trial ( placebo controlled, did not include low stage patients and used a higher dose of bevacizumab), it might be the best possible validation cohort to date 7, 8 . Furthermore, newer gene expression assays, like the NanoString platform, which can be used in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory to molecular subtype ovarian cancer patients, open the possibility of prospective clinical trials to enrich for specific molecular subtypes 25, 26 . Furthermore, our group is currently initiating an investigator initiated Phase II, open-label, single-arm, multi-center study to evaluate efficacy and safety of pembrolizumab monotherapy in subjects with advanced epithelial ovarian cancer whose tumor specimens demonstrate an immunoreactive gene expression signature. We will utilize the NanoString platform in a CLIA certified laboratory to screen and classify patients into one of the four molecular subtypes using FFPE tumor tissue. The same approach could be used to conduct prospective trials enriching for patients with molecular subtypes deriving more possible benefit from treatment with bevacizumab.
In summary, the present investigation is the first to examine the correlation of molecular subtype with outcome after treatment with bevacizumab in a randomized controlled phase III trial of primary ovarian cancer. We showed that women with the proliferative and mesenchymal molecular subtypes appear to benefit most, with a prolongation in PFS and a trend toward greater OS. Validation of our findings in an independent cohort, like GOG 218 could enable the targeted use of bevacizumab for selected patients, based on their molecular subtype. 
